Answers are grounded in this paper and cite their sources.
The trough concentration (Cmin) of linezolid (LEN) is closely associated with therapeutic efficacy and adverse reactions in patients with complex Gram-positive bacterial infections. However, substantial inter- and intra-individual variability exists in plasma concentrations of this drug. Therefore, therapeutic drug monitoring (TDM) is strongly recommended. This study aimed to establish a rapid and simple two-dimensional high-performance liquid chromatography (2D-HPLC) method for determining plasma LEN concentrations for TDM and providing a scientific basis for its rational clinical use. A Shimadzu LC-20AT system coupled with a Demeter FLC-280 was employed. Detection was performed using an ultraviolet detector at a wavelength of 254 nm. The injection volume was 50 μl, and the column temperature was maintained at 40 ℃. Additionally, 197 plasma samples were collected from patients receiving LEN for anti-infective therapy. LEN was successfully quantified using this method, which achieved good separation and an analysis time of 10 min per run. The calibration curve exhibited excellent linearity within the range of 0.20−20.19 mg/L, with an extraction rate exceeding 95%. Accuracy, precision, recovery, and stability were all within acceptable limits. The minimum concentration (Cmin) of the drug in patients was measured using the validated method. The 2D-HPLC method is simple, stable, and highly automated, which greatly improves real-time LEN detection during routine TDM in hospitals. Adjusting dosing regimens based on test results and patient-specific information may facilitate rational and safe clinical use of the drug.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: